The University of Colorado Anschutz Medical Campus is collaborating with the National Institutes of Health’s National Institute of Allergy and Infectious Disease (NIAID) to conduct a clinical trial known as LATITUDE (Long-Acting Therapy to Improve Treatment Success in Daily Life). The study sponsor, NIAID, seeks to understand if monthly injections of anti-viral drugs are better at suppressing the HIV virus than daily pill regimen.
University of Colorado Anschutz Medical Campus is the lead investigative site along with Alabama CTU. They will test whether two experimental injectable drug formulations of antiretroviral therapy (ART) are superior to daily pills.
One premise behind the injectables involves the hope of keeping drug concentrations in the blood in a more steady and consistent manner. According to ClinicalTrials.gov, approximately 350 patients will be enrolled with documented treatment lapses within the last 18 months will be enrolled in the study for 52 weeks. HIV is far more manageable now, but obstacles remain, and a lack of steady medication adherence can lead to dangerous to deadly flare ups—especially in at risk populations.
Jose Castillo-Mancilla, MD, associate professor of medicine, University of Colorado
Aadia Rana, MD, Alabama CTU